勃林格殷格翰携手多方，共话代谢相关脂肪性肝炎防治的中国方案

Core Viewpoint - The event hosted by Boehringer Ingelheim at the China International Import Expo focused on discussing the prevention and treatment strategies for Metabolic Associated Steatotic Liver Disease (MASH) in China, highlighting the need for research and a comprehensive management system for the disease [1][3]. Group 1: Disease Overview - MASH is closely related to metabolic disorders, with its prevalence rising significantly due to increasing rates of obesity and diabetes, making it a major global health challenge [1]. - Approximately 20% of MASH cases may progress to liver fibrosis, cirrhosis, or even liver cancer, posing serious health risks beyond liver disease itself [2]. Group 2: Treatment and Innovation - There is a limited availability of targeted treatment options for MASH in China, with a pressing clinical need for innovative therapies that can significantly benefit patients with MASH and fibrosis [2]. - Boehringer Ingelheim is accelerating the development of its innovative drug, survodutide, which is a dual agonist of the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R), expected to provide new treatment options for patients with obesity and MASH [2]. Group 3: Research and Collaboration - Experts at the event emphasized the urgency of conducting research on the disease burden of MASH in the Chinese population and developing a disease database that reflects the true health status and experiences of patients [3]. - Boehringer Ingelheim is committed to driving innovation in the field of cardiometabolic diseases and advocates for collaboration among government, industry, academia, and society to address the challenges posed by chronic diseases [3].